BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 23, 2004
View Archived Issues
Oral agents effective against murine cytomegalovirus in vivo
Read More
Promising liver-selective thyromimetic for the treatment of hepatocellular carcinoma
Read More
Three series of antibacterial oxazolidinones patented by Pfizer
Read More
Novel chemokine CCR2B antagonists identified at Janssen
Read More
New metal-chelating alphavbeta3 integrin antagonists and their use
Read More
GSK researchers describe new SGK-1 inhibitors and their use
Read More
Novel phospholipase A2 inhibitors in early development at Merckle
Read More
New antibacterial oxazolidinones under evaluation at Ranbaxy
Read More
Positive preliminary results from second phase III trial of CDP-870 in RA
Read More
Anticancer compound WX-671 enters clinical development
Read More
New intravenous formulation of MC-1 gives positive phase I results
Read More
Phase III clinical trials of Aquavan commence
Read More
Phase III trial for Ceplene fails to meet primary endpoint
Read More
Vicuron provides update on the NDA status of anidulafungin
Read More
Antiinflammatory and therapeutic effects of ciclesonide in asthma
Read More
Viral-specific immune responses induced with multiple-epitope vaccines for HIV-1 and SIV
Read More
DOR BioPharma completes a pivotal trial with orBec in GvHD
Read More
4SC and Mutabilis collaborate to identify new molecules against infectious diseases
Read More
PD-332991 enters phase I
Read More
Extended Aranesp dosing approved by European Commission
Read More
Tarceva plus gemcitabine combination improves survival in pancreatic cancer patients
Read More
The EMEA accepts marketing authorization application for Macugen
Read More
IDM cleared to begin U.S. phase II trial of Uvidem
Read More
ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity
Read More
Prasterone active in systemic lupus erythematosus
Read More
Insight into mechanism of action of analgesic GR-242468
Read More
Business plans at Savient
Read More